The
2012 SFEE Code of Practice implements significant changes with respect to the conduct of non-interventional studies in Greece so please do read the code in detail!

The following, provides a brief overview of the changes.
When is the 2012 in Force?From 2nd April 2012
So Whats New?The
2010 SFEE Code of Practice caused some challenges confusion by grouping Clinical Trials with Epidemiological Trials, whilst separately addressing Non interventional trials.
The
2012 SFEE Code of Practice has addressed this by the guidance on Non-Interventional Trials with Pharmacoepidemiological Trials and dealing with Interventional Clinical Trials separately
Competent Authority Approval (EOF)The only type of non-interventional/pharmacoepidemiological trials which
are from now on submitted to EOF are the non-interventional post marketing
studies of safety or efficacy which are required by the competent authority either at the granting of the marketing authorization or later and which are subject to EOF's prior approval (as per Section 29.3 of the
2012 SFFE COP)
Refer to:
CIRCULAR 17079/4-3-2011 - Clarification Instructions on non-interventional studiesMarket ResearchThe following section has been added to requirements for Market Research (Article 27):
- The data collected by the healthcare professionals concerning patients must be cumulative. In a market research no personal data of the patients must be collected because in such a case it is considered as a non interventional/pharmacoepidemiological trial and it is covered by the provisions of article 29.
Further Diagnostic ProceduresThe
2010 SFEE Code of Practice stated:
- No further diagnostic or follow-up procedure shall be imposed on the patients, nor will epidemiological methods be used for the analysis of collected data.
The
2012 SFEE Code of Practice now states:
- No further diagnostic or follow-up procedure shall be imposed on the patients, and epidemiological methods will be used for the analysis of data collected according to the principles of Vol 9A.
Increased Scope- 2010 SFEE Code of Practice: Prospective Non-interventional trials
- 2012 SFEE Code of Practice: Non-interventional/ pharmacoepidemiological clinical trials for medicinal products, of prospective or retrospective nature
Study Approval and RegistrationThe trial protocol must be submitted for evaluation to the competent
committees (scientific or deontology committees) and uploaded to an online
registry of clinical trials, which has free access to the public (as per Section 29.2.d of the
2012 SFFE COP)
Before the beginning of the trial, the basic characteristics of the trial must
be recorded in a special registry with free access to the public (as per Section 29.2.h of the
2012 SFFE COP)
The pharmaceutical company must send the brief report to all healthcare professionals participating in the trial and must record it to a special registry of noninterventional/ pharmacoepidemiological trials (as per Section 29.2.i of the
2012 SFFE COP)
Involvement of Medical Sales RepresentativesMedical sales representatives are not allowed to be involved in the conduct
of the trial (as per Section 29.2.j of the
2012 SFFE COP)
Provision for the Organization of Scientific EventsThis section has been significantly updated and the types of event split into types A, B or C. Each of which has differing approval requirements. Note that all scientific events will need prior approval from the National Competent Authority (EOF).
Refer to Sections 21 to 23 of the
2012 SFEE COP for further details